TherapeuticsMD

Yahoo Finance • 6 months ago

FDA to remove “black box” warnings on hormone therapies for menopause

[FDA Headquarters - White Oak Campus] hapabapa Marking a pivotal moment in women’s health, the U.S. Food and Drug Administration (FDA) on Monday initiated actions to remove “black box” warnings, the agency’s strongest safety alert, from h... Full story

Yahoo Finance • 2 years ago

12 Best Prenatal Vitamins For Pregnant Women

In this article, we will be taking a look at the 12 best prenatal vitamins for pregnant women. If you are not interested in reading about the market insights, head straight to the 5 Best Prenatal Vitamins For Pregnant Women. Discovering t... Full story

Yahoo Finance • 2 years ago

TherapeuticsMD Announces Third Quarter 2023 Financial Results

Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives BOCA RATON, Fla., November 14, 2023--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company"... Full story

Yahoo Finance • 3 years ago

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

- TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in... Full story

Yahoo Finance • 4 years ago

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch VIENNA, Va., August 08, 2022--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the appoin... Full story

Yahoo Finance • 4 years ago

THERAPEUTICSMD ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TXMD and Encourages Investors to Contact the Firm

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of TherapeuticsMD, Inc. (NASDAQ: TXMD) bre... Full story